To report the effects of high-dose corticosteroid therapy in a patient with autoimmune glial fibrillary acidic protein astrocytopathy and discuss its clinical significance.
Key Findings:
Marked clinical improvement post corticosteroid therapy.
Neuroimaging findings also improved significantly.
No long-term outcomes or recurrence data were reported, highlighting the need for further studies.
Interpretation:
High-dose corticosteroids may provide significant benefits in managing autoimmune GFAP astrocytopathy, particularly in acute presentations, but further studies are needed.
Limitations:
Single-patient case report without comparator groups, limiting generalizability.
Descriptive findings with no quantitative effect estimates, which may affect the interpretation of results.
Lack of long-term follow-up data, which is crucial for understanding the durability of treatment effects.
Conclusion:
Autoimmune GFAP astrocytopathy should be considered in patients with specific symptoms and MRI features; high-dose corticosteroids are a first-line treatment, but further research is warranted.
